Skip to content

PaterGrus

Active
Private limited companyfounded 2007active for 18 yearsSparhoekdreef 57, 9880 Aalter, BelgiumKBO/BCE: BE 0894.473.721
Summary

PaterGrus has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €44,294 and a net result of -€19,029. Equity is shrinking by about 12% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.6% (low).

Financials · financial year 2025, micro format

Equity
€44,294▼ 30.1%
2024 · €63,323
Total assets
€185,505▲ 5.0%
2024 · €176,694
Net result
-€19,029▼ 29.2%
2024 · -€14,724
Working capital
-€23,286▼ 287%
2024 · -€6,010
Trend over the years

2021 to 2025, 5 financial years 2019 to 2025, 7 financial years

The operating result stays negative: a loss of €12,517 in 2025 against €10,664 in 2024; the loss grows.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result-€12,517 2025 Net result-€19,029 2025

Use the arrow keys on the chart for the figures per year.

Every figure with its change against the financial year before
favourable unfavourable
Line2019202020212022202320242025
Operating result€32,213--€4,828-€76,124▼ 1,477%€56,279€15,627▼ 72.2%-€10,664-€12,517▼ 17.4%
Net result€23,677--€9,807-€80,270▼ 719%€51,804€10,698▼ 79.3%-€14,724-€19,029▼ 29.2%
Equity€104,622-€94,816▼ 9.4%€14,546▼ 84.7%€66,350▲ 356%€77,047▲ 16.1%€63,323▼ 17.8%€44,294▼ 30.1%
Total assets€261,261-€284,867▲ 9.0%€219,427▼ 23.0%€290,335▲ 32.3%€233,724▼ 19.5%€176,694▼ 24.4%€185,505▲ 5.0%
Debt€156,638-€190,051▲ 21.3%€204,882▲ 7.8%€223,986▲ 9.3%€156,677▼ 30.1%€113,371▼ 27.6%€141,211▲ 24.6%
Working capital€36,806-€18,574▼ 49.5%-€57,942-€2,077▲ 96.4%€4,087-€6,010-€23,286▼ 287%
Turnover and EBIT margin not published: the micro format does not require them.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €185,505
Fixed assets €106,134 ▼ 10.7%
Current assets €79,371 ▲ 37.1%
Equity and liabilities €185,505
Equity €44,294 ▼ 30.1%
Debt €141,211 ▲ 24.6%
Debt's share of the balance-sheet total rises from 64.2% to 76.1%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€167▼
2024 · €3,613
Cash flow
-€6,345▼
2024 · -€447
Current ratio
0.77▼
2024 · 0.91
Debt to equity
3.19▲
2024 · 1.79
ROE
-43.0%▼
2024 · -23.3%
ROA
-10.3%▼
2024 · -8.3%
Interest coverage
0.03▼
2024 · 0.61
Debt ≤ 1 year
€102,657▲
2024 · €63,887
Debt > 1 year
€38,554▼
2024 · €49,484
Income taxes
€533▲
2024 · €460
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 1,294 companies that looked in July 2024 the way this one looks now, 4.1% went bankrupt within 24 months and 89.6% are still going.

  • Micro
  • 10 to 20 years old
  • solvency 10 to 30%
  • a loss of 10% of the balance sheet or more
4.1% went bankrupt
6.0% stopped otherwise
89.6% still going

A further 0.4% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 0.6% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 1,294 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 47 lines
Balance sheet Code20242025
Assets
Total assets20/58€176,694€185,505▲
Fixed assets21/28€118,818€106,134▼
Tangible fixed assets22/27€118,818€106,134▼
Land and buildings22€110,955€101,190▼
Plant, machinery and equipment23€6,016€4,412▼
Furniture and vehicles24€1,847€532▼
Current assets29/58€57,876€79,371▲
Amounts receivable within one year40/41€39,773€73,150▲
Trade receivables40€39,054€72,615▲
Other amounts receivable41€719€535▼
Current investments50/53€0-
Cash at bank and in hand54/58€14,717€5,238▼
Deferred charges and accrued income490/1€3,386€983▼
Equity and liabilities
Total equity and liabilities10/49€176,694€185,505▲
Equity10/15€63,323€44,294▼
Contributions10/11€19,000€19,000=
Reserves13€61,941€61,941=
Non-distributable reserves130/1€0-
Reserves not available under the articles1311€0-
Distributable reserves133€61,941€61,941=
Profit (loss) carried forward14-€17,618-€36,647▼
Amounts payable17/49€113,371€141,211▲
Amounts payable after more than one year17€49,484€38,554▼
Financial debts170/4€49,484€38,554▼
Amounts payable within one year42/48€63,887€102,657▲
Current portion of amounts payable after more than one year42€18,150€18,430▲
Financial debts43€76€0▼
Credit institutions430/8€76€0▼
Trade debts44€2,775€3,469▲
Suppliers440/4€2,775€3,469▲
Taxes, remuneration and social security45€2,133€971▼
Taxes450/3€2,133€971▼
Other amounts payable47/48€40,752€79,787▲
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€14,277€12,684▼
Other operating charges640/8€1,026€2,475▲
Gross operating margin9900€4,639€2,642▼
Operating profit (loss)9901-€10,664-€12,517▼
Financial income75/76B€2,302€15▼
Recurring financial income75€2,302€15▼
Financial charges65/66B€5,902€5,995▲
Recurring financial charges65€5,902€5,995▲
Profit (loss) for the period before taxes9903-€14,265-€18,497▼
Income taxes67/77€460€533▲
Profit (loss) for the period9904-€14,724-€19,029▼
Profit (loss) for the period to be appropriated9905-€14,724-€19,029▼
Appropriation of the result
Profit (loss) to be appropriated9906-€17,618-€36,647▼
Profit (loss) brought forward from the previous period14P-€2,894-€17,618▼

The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2019202020212022202320242025Change
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€14,178€16,343€16,039€15,702€15,934€14,277€12,684▼ 11.2%
Other operating charges640/8--€468€1,002€764€1,026€2,475▲ 141%
Non-recurring operating charges66A---€1,037€0---
Gross operating margin9900€46,965€12,107-€59,617€74,020€32,325€4,639€2,642▼ 43.0%
Operating profit (loss)9901€32,213-€4,828-€76,124€56,279€15,627-€10,664-€12,517▼ 17.4%
Financial income75/76B--€1,171€2,493€365€2,302€15▼ 99.3%
Recurring financial income75€188€129€1,171€2,493€365€2,302€15▼ 99.3%
Financial charges65/66B--€4,895€6,519€4,772€5,902€5,995▲ 1.6%
Recurring financial charges65€5,818€4,715€4,895€6,519€4,772€5,902€5,995▲ 1.6%
Profit (loss) for the period before taxes9903€26,583-€9,415-€79,847€52,252€11,219-€14,265-€18,497▼ 29.7%
Income taxes67/77€2,906€392€423€448€522€460€533▲ 15.9%
Profit (loss) for the period9904€23,677-€9,807-€80,270€51,804€10,698-€14,724-€19,029▼ 29.2%
Profit (loss) for the period to be appropriated9905€23,677-€9,807-€80,270€51,804€10,698-€14,724-€19,029▼ 29.2%
Line2019202020212022202320242025Change
Assets
Total assets20/58€261,261€284,867€219,427€290,335€233,724€176,694€185,505▲ 5.0%
Fixed assets21/28€167,889€166,715€153,109€138,937€133,095€118,818€106,134▼ 10.7%
Tangible fixed assets22/27€167,889€166,715€153,109€138,937€133,095€118,818€106,134▼ 10.7%
Land and buildings22--€140,250€130,485€120,720€110,955€101,190▼ 8.8%
Plant, machinery and equipment23--€643€1,740€7,817€6,016€4,412▼ 26.7%
Furniture and vehicles24--€12,216€6,712€4,558€1,847€532▼ 71.2%
Current assets29/58€93,372€118,152€66,318€151,398€100,629€57,876€79,371▲ 37.1%
Amounts receivable within one year40/41€33,154€53,786€30,092€68,447€60,972€39,773€73,150▲ 83.9%
Trade receivables40--€27,029€68,197€59,532€39,054€72,615▲ 85.9%
Other amounts receivable41--€3,063€251€1,440€719€535▼ 25.6%
Current investments50/53€17,814€26,340€25,575€12,413€11,303€0--
Cash at bank and in hand54/58€39,693€31,775€4,096€65,993€21,962€14,717€5,238▼ 64.4%
Deferred charges and accrued income490/1--€6,555€4,545€6,393€3,386€983▼ 71.0%
Equity and liabilities
Total equity and liabilities10/49€261,261€284,867€219,427€290,335€233,724€176,694€185,505▲ 5.0%
Equity10/15€104,622€94,816€14,546€66,350€77,047€63,323€44,294▼ 30.1%
Contributions10/11€18,000-€18,000€18,000€18,000€19,000€19,000=
Reserves13€61,941€61,941€61,941€61,941€61,941€61,941€61,941=
Non-distributable reserves130/1--€1,900€1,900€1,900€0--
Reserves not available under the articles1311--€1,900€1,900€1,900€0--
Distributable reserves133--€60,041€60,041€60,041€61,941€61,941=
Profit (loss) carried forward14€24,681€14,875-€65,395-€13,591-€2,894-€17,618-€36,647▼ 108%
Amounts payable17/49€156,638€190,051€204,882€223,986€156,677€113,371€141,211▲ 24.6%
Amounts payable after more than one year17€100,073€90,474€80,622€70,511€60,134€49,484€38,554▼ 22.1%
Financial debts170/4--€80,622€70,511€60,134€49,484€38,554▼ 22.1%
Amounts payable within one year42/48€56,566€99,578€124,260€153,475€96,542€63,887€102,657▲ 60.7%
Current portion of amounts payable after more than one year42--€17,352€17,611€17,877€18,150€18,430▲ 1.5%
Financial debts43--€3,599€429€88€76€0▼ 100%
Credit institutions430/8--€3,599€429€88€76€0▼ 100%
Trade debts44€21,683€7,606€10,935€20,294€13,743€2,775€3,469▲ 25.0%
Suppliers440/4--€10,935€20,294€13,743€2,775€3,469▲ 25.0%
Advances received on contracts in progress46--€42,434€45,471€0---
Taxes, remuneration and social security45--€2,372€11,468€520€2,133€971▼ 54.5%
Taxes450/3--€2,372€11,468€520€2,133€971▼ 54.5%
Remuneration and social security454/9--€0-----
Other amounts payable47/48--€47,569€58,202€64,314€40,752€79,787▲ 95.8%
Line2019202020212022202320242025Change
Profit (loss) for the period9904€23,677-€9,807-€80,270€51,804€10,698-€14,724-€19,029▼ 29.2%
+ Depreciation and write-downs630€14,178€16,343€16,039€15,702€15,934€14,277€12,684▼ 11.2%
Operating cash flow (approximation)€37,855€6,537-€64,231€67,506€26,632-€447-€6,345▼ 1,319%
Investment in fixed assets (approximation)--€15,169-€2,434-€1,530-€10,091€0€0-
Change in cash--€7,918-€27,679€61,897-€44,031-€7,245-€9,479▼ 30.8%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 15 filings with the National Bank
Financial year Type Filed Reference
30-09-2025 micro format 30-04-2026 2026-00099789
30-09-2024 micro format 15-05-2025 2025-00101702
30-09-2023 micro format 24-04-2024 2024-00073198
30-09-2022 micro format 15-05-2023 2023-00092439
30-09-2021 micro format 28-04-2022 2022-20014149
30-09-2020 micro format 30-04-2021 2021-12400327
30-09-2019 micro format 30-04-2020 2020-10400248
30-09-2018 micro format 05-06-2019 2019-15800229
30-09-2017 micro format 27-04-2018 2018-10800206
30-09-2016 abbreviated format 05-05-2017 2017-11400516

Show all 15 filings

Subsidies and aid

European Union, budget

2021 · 2 entries · €221,814 in total
Projects
TIGER - PROOF OF PRINCIPLE OF THE BEST-IN-CLASS THERAPEUTIC MRNA CANCER VACCINE
Horizon Europe · 01-02-2021 to 31-07-2025 · €221,814

European research

5 projects · €1.1m EU contribution
Programmes
4 entries · €934,674
1 entry · €198,810
Projects
Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication
Horizon 2020 · participant · 01-05-2015 to 31-12-2017 · €330,085 · PRO-CF-MED
Personalised Treatment For Cystic Fibrosis Patients With Ultra-rare CFTR Mutations (and beyond)
Horizon 2020 · participant · 01-01-2018 to 30-06-2025 · €302,075 · HIT-CF
Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine
Horizon 2020 · participant · 01-02-2021 to 31-07-2025 · €221,813 · TIGER
First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH
Seventh Framework Programme · participant · 01-07-2012 to 31-07-2017 · €198,810 · FIGHT-HLH
SUpport and PartnERship for the development of multiple sustainable and market ready value chains in the BIObased economy
Horizon 2020 · participant · 01-06-2016 to 31-03-2019 · €80,701 · SUPERBIO

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.